Skip to content
← Catalog

Lancet 2025 · In-vivo BCMA CAR T-cell therapy for r/r MM (ESO-T01 companion)

[No abstract available · Lancet letter-type article 不附 abstract] Per Lancet 2025-07-19 letter · 描述 ESO-T01 in vivo BCMA CAR-T 在 r/r multiple myeloma 9-patient 队列的较早期数据 · companion to Nature Medicine 2026 (PMID 41882404) phase 1 report

Type
paper
Domain
oncology
Grade
conference
License
LIGHT_HOPE_proprietary
Provenance
m622_intel_seed_2026-05-16
evidence_grade
A
category
in_vivo_car_t_clinical_paper
status
verified
instance_tag
sunvax-antibody-2025
clinical_claim_softening
"early phase 1 clinical data · NOT validated late-stage outcome"
journal
Lancet
year
2025
authors
Jia Xu,Heng Mei
abstract_snippet
[No abstract available · Lancet letter-type article 不附 abstract] Per Lancet 2025-07-19 letter · 描述 ESO-T01 in vivo BCMA CAR-T 在 r/r multiple myeloma 9-patient 队列的较早期数据 · companion to Nature Medicine 2026 (PMID 41882404) phase 1 report
pmid
40617243
doi
10.1016/S0140-6736(25)01030-X
View at source ↗

Read-only aggregated view. Conference Library is the source of record; this catalog shows provenance as-is — no ratings, no reviews.